EUVIMEDEUVIMED entdecken
Open Access

Pharmacogenetics of steady-state metabolism, pharmacokinetics, and adverse effects of voriconazole in healthy participants

Yanting Phoebe Wu, Ayşe Gelal, Chisook Moon, Ingrid F Metzger, Jessica B L Lu, John T Callaghan, Todd C Skaar, Zeruesenay Desta

Drug Metabolism and Disposition · 2025

DOI: 10.1016/j.dmd.2025.100156 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Metabolism and Disposition, 2025. Verfasst von Yanting Phoebe Wu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana. Hauptthemen laut MEDLINE: Voriconazole, Antifungal Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, National Institutes of Health, NIH National Institute of General Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Voriconazole, a broad-spectrum antifungal, exhibits significant interpatient variability in efficacy and safety. This study assessed the influence of genetic and nongenetic factors on its steady-state pharmacokinetics and adverse effects. In vitro studies characterized voriconazole metabolism. An ancillary analysis was conducted on data from a completed trial involving 61 healthy participants who received a loading dose of 400 mg twice daily on first day, followed by 200 mg twice daily for 8 days. On the third day of voriconazole treatment, plasma and urine samples were collected over a 12-hour period after dose administration. Multiple trough concentrations, adverse events, and laboratory values were recorded throughout the study. Voriconazole and its metabolites were quantified using liquid chromatography-tandem mass spectrometry methods. Genotyping for CYP2C9, CYP2C19, CYP3A4, and CYP3A5 variants was performed using TaqMan assays. In vitro, CYP2C19 predominantly catalyzed the formation of voriconazole N-oxide and methyl hydroxy voriconazole, whereas CYP3A4/5 catalyzed fluoropyrimidine ring hydroxylation. Steady-state voriconazole area under the concentration-time curve (AUC0-ԏ) was significantly associated with CYP2C19 genotypes (P < .01); over 9-fold reduction in AUC0-ԏ was noted in CYP2C19 ∗17/∗17 genotype compared with CYP2C19 ∗2/∗2 carriers. We identified voriconazole N-glucuronide in plasma for the first time. Noncompliant subjects exhibited lower voriconazole exposure (P = .0002). Visual and neurologic/psychiatric adverse effects occurred in 79.7% and 72.9% of subjects, respectively, predominantly during the loading dose phase, but showed no association with CYP2C19 genotypes. No liver abnormalities were observed. CYP2C19 polymorphisms and medication adherence significantly influence voriconazole pharmacokinetics but not safety outcomes. These findings support the consideration of CYP2C19 genotyping and adherence monitoring to optimize voriconazole therapy. SIGNIFICANCE STATEMENT: This study elucidated genetic and nongenetic factors contributing to interindividual variability in voriconazole pharmacokinetics and adverse effects. In vitro analyses identified CYP2C19 as the primary enzyme mediating voriconazole metabolism, with CYP3A4/5 playing a secondary role. In vivo, CYP2C19 polymorphisms and noncompliance significantly influenced voriconazole exposure. Mild visual and neurological/psychiatric symptoms were common during the loading phase. These findings support incorporating CYP2C19 genotyping and adherence monitoring into voriconazole dosing strategies to optimize therapeutic outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

VoriconazoleAntifungal AgentsHumansMaleAdultFemaleHealthy VolunteersCytochrome P-450 CYP2C19GenotypeYoung AdultMiddle AgedCytochrome P-450 CYP3APharmacogenetics

Stichwörter der Autor:innen

Adverse effectsCYP2C19 genotypesMetabolismPharmacogenomicsPharmacokineticsVoriconazole

Substanzen

VoriconazoleAntifungal AgentsCytochrome P-450 CYP2C19Cytochrome P-450 CYP3ACYP2C19 protein, human

Autor:innen und Institutionen

  • Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana.
  • Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana. Electronic address: zdesta@iu.edu.

Förderung

  • NIGMS NIH HHS
  • National Institutes of Health
  • NIH National Institute of General Medical Sciences

Zitieren

APA

Wu, Y. P., Gelal, A., Moon, C., Metzger, I. F., Lu, J. B. L., Callaghan, J. T., Skaar, T. C., & Desta, Z. (2025). Pharmacogenetics of steady-state metabolism, pharmacokinetics, and adverse effects of voriconazole in healthy participants. Drug Metabolism and Disposition. https://doi.org/10.1016/j.dmd.2025.100156

Vancouver

Wu YP, Gelal A, Moon C, Metzger IF, Lu JBL, Callaghan JT, et al. Pharmacogenetics of steady-state metabolism, pharmacokinetics, and adverse effects of voriconazole in healthy participants. Drug Metabolism and Disposition. 2025. doi:10.1016/j.dmd.2025.100156

BibTeX
@article{Wu2025,
  author = {Wu, Yanting Phoebe and Gelal, Ayşe and Moon, Chisook and Metzger, Ingrid F and Lu, Jessica B L and Callaghan, John T and Skaar, Todd C and Desta, Zeruesenay},
  title = {Pharmacogenetics of steady-state metabolism, pharmacokinetics, and adverse effects of voriconazole in healthy participants},
  journal = {Drug Metabolism and Disposition},
  year = {2025},
  doi = {10.1016/j.dmd.2025.100156}
}
Kostenlos starten →